These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16760174)

  • 1. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
    Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
    Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
    Kretschmer L; Helmbold P; Emmert S; Marsch WC
    Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
    Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
    Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
    J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
    Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
    Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
    J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
    J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS; Neuberg D; Park Y; Kirkwood JM
    Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
    Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant chemotherapy as a component of complex treatment for skin melanoma].
    Kudriavtsev DV; Kudriavtseva GT; Mardynskiĭ IuS
    Vopr Onkol; 2008; 54(2):170-7. PubMed ID: 18522165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of supportive care with or without CVD chemotherapy as a second-line treatment in advanced melanoma by patient's choice: a multicentre Dermatologic Cooperative Oncology Group trial.
    Hofmann MA; Hauschild A; Mohr P; Garbe C; Weichenthal M; Trefzer U; Drecoll U; Tilgen W; Schadendorf D; Kaatz M; Ulrich J
    Melanoma Res; 2011 Dec; 21(6):516-23. PubMed ID: 22076216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
    Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
    J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of a randomized polychemotherapy study in malignant melanoma].
    Fiedler H; Hetschko I; Wohlrab W; Wozniak KD; Lübbe D; Taube KM
    Hautarzt; 1990 Jul; 41(7):369-74. PubMed ID: 1698185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, randomized, multicenter, double-blind placebo-controlled trial comparing adjuvant interferon alfa and isotretinoin with interferon alfa alone in stage IIA and IIB melanoma: European Cooperative Adjuvant Melanoma Treatment Study Group.
    Richtig E; Soyer HP; Posch M; Mossbacher U; Bauer P; Teban L; Svolba G; Wolf IH; Fritsch P; Zelger B; Volc-Platzer B; Gebhart W; Mischer P; Steiner A; Pachinger W; Hintner H; Gschnait F; Rappersberger K; Pilarski P; Pehamberger H;
    J Clin Oncol; 2005 Dec; 23(34):8655-63. PubMed ID: 16260701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
    Neri B; Vannozzi L; Fulignati C; Pantaleo P; Pantalone D; Paoletti C; Perfetto F; Turrini M; Mazzanti R
    Cancer Invest; 2006; 24(5):474-8. PubMed ID: 16939954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
    Gershanovich ML; Akimov MA
    Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    Schippinger W; Samonigg H; Schaberl-Moser R; Greil R; Thödtmann R; Tschmelitsch J; Jagoditsch M; Steger GG; Jakesz R; Herbst F; Hofbauer F; Rabl H; Wohlmuth P; Gnant M; Thaler J;
    Br J Cancer; 2007 Oct; 97(8):1021-7. PubMed ID: 17895886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.